Utility of galectin-3 in predicting post-infarct remodeling after acute myocardial infarction based on extracellular volume fraction mapping
| Autor: | Roger Borràs, Antonio Berruezo, Xavier Bosch, David Andreu, Teresa M. de Caralt, Lluís Mont, Rosario J. Perea, Manuel Morales-Ruiz, James Donnelly, Luis Lasalvia, M. Martinez, Blai Morales-Romero, Wladimiro Jiménez, José T. Ortiz-Pérez, Diego Penela, Susanna Prat-Gonzalez, Aurea Mira, Juan Acosta |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
medicine.medical_specialty Galectin 3 Magnetic Resonance Imaging Cine 030204 cardiovascular system & hematology Ventricular Function Left 030218 nuclear medicine & medical imaging 03 medical and health sciences 0302 clinical medicine Interstitial space Fibrosis Internal medicine Humans Medicine Prospective Studies cardiovascular diseases Myocardial infarction Ejection fraction Extracellular volume fraction Ventricular Remodeling medicine.diagnostic_test business.industry Myocardium Magnetic resonance imaging Middle Aged Prognosis medicine.disease Infarct size Extracellular Matrix Galectin-3 Cardiology ST Elevation Myocardial Infarction Female Cardiology and Cardiovascular Medicine business Biomarkers Follow-Up Studies |
| Zdroj: | International Journal of Cardiology. 223:458-464 |
| ISSN: | 0167-5273 |
| DOI: | 10.1016/j.ijcard.2016.08.070 |
| Popis: | Aims ST-segment elevation myocardial infarction (STEMI) triggers remote extracellular matrix expansion. Myocardial extracellular volume fraction (ECV), determined by cardiovascular magnetic resonance, permits quantification of interstitial space expansion. Our aim was to determine the relationship between early serum fibrosis biomarkers and 180-day post-infarct remote myocardium remodeling using ECV. Methods and results In 26 patients with STEMI, functional imaging, T1-mapping, and late-gadolinium-enhancement were performed on a 3-T CMR scanner at baseline (days 3 to 5) and 180days. Biomarkers were measured at days 1, 3, and 7 after STEMI. The mean initial and follow-up left ventricular ejection fraction (LVEF) were 48.3±18.1% and 52.6±12.3%, respectively. Initial infarct size was 11.6±16.8% of LV mass. ECV in the remote myocardium at 180days correlated with indexed end-systolic volume (r=0.4, p=0.045). A significant correlation was observed between galectin-3 at day 7 and ECV at 6months (r=0.428, p=0.037). A trend towards a direct correlation was found for BNP (r=0.380, p=0.059). Multivariate analysis revealed that BNP and galectin-3 were independent predictors of long-term changes in ECV and explained nearly 30% of the variance in this parameter (r 2 =0.34; p=0.01). A galectin-3 cutoff value of 10.15ng/mL was the most powerful predictor of high ECV values (≥28.5%) at follow-up. Galectin-3 at day 7 was an independent predictor of high ECV values at follow-up (OR=22.51; CI 95%: 2.1–240.72; p=0.01) with 0.76 AUC (CI: 0.574–0.964; p=0.03). Conclusions Galectin-3 measured acutely after STEMI is an independent predictor of increased ECV at 6-month follow-up that might be useful for long-term risk stratification. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect